1. Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)
- Author
-
Alain Saraux, Jacques-Olivier Pers, Tinhinane Fali, Enrique Montero, Ruby Alonso, Valérie Devauchelle, Yves Renaudineau, Christelle Le Dantec, LabEX IGO Immunothérapie Grand Ouest, Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Experimental Immunotherapy, La Habana, Cuba, Center for molecular Immunology, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), and Laboratoire d'Immunologie et Immunothérapie
- Subjects
Antigens, Differentiation, T-Lymphocyte ,T-Lymphocytes ,Itolizumab ,MESH: Flow Cytometry ,Cell Separation ,Lymphocyte Activation ,Protein Engineering ,Salivary Glands ,MESH: Protein Structure, Tertiary ,0302 clinical medicine ,Cell Movement ,MESH: Cell Movement ,MESH: Antigens, CD ,Receptors, Scavenger ,B-Lymphocytes ,0303 health sciences ,Flow Cytometry ,3. Good health ,MESH: Protein Engineering ,Sjogren's Syndrome ,Rheumatoid arthritis ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Clone (B-cell biology) ,medicine.drug ,MESH: Salivary Glands ,medicine.drug_class ,Immunology ,Antibodies, Monoclonal, Humanized ,Monoclonal antibody ,MESH: Cell Separation ,MESH: Cell Adhesion ,03 medical and health sciences ,MESH: Activated-Leukocyte Cell Adhesion Molecule ,Antigens, CD ,Cell surface receptor ,MESH: B-Lymphocytes ,Activated-Leukocyte Cell Adhesion Molecule ,Cell Adhesion ,medicine ,Humans ,MESH: Receptors, Scavenger ,Scavenger receptor ,MESH: Lymphocyte Activation ,ALCAM ,030304 developmental biology ,030203 arthritis & rheumatology ,MESH: Humans ,business.industry ,Multiple sclerosis ,medicine.disease ,Protein Structure, Tertiary ,MESH: Sjogren's Syndrome ,MESH: T-Lymphocytes ,MESH: Antigens, Differentiation, T-Lymphocyte ,MESH: Antibodies, Monoclonal, Humanized ,business - Abstract
International audience; CD6 is a cell surface receptor expressed on the majority of T cells and a subset of B cells. When expressed, CD6 contributes to lymphocyte activation through its extracellular domain 1, while adhesion and cellular migration are related to the extracellular scavenger receptor cysteine-rich domain (SRCR-D)-3 of CD6. Itolizumab, clone T1h, is a newly developed humanized IgG1 monoclonal antibody that targets CD6 SRCR-D1 and blocks immune activation. Itolizumab has been proposed to be effective in autoimmune diseases such as rheumatoid arthritis, Sjögren's syndrome and multiple sclerosis. In Sjögren's syndrome, the utilization of itolizumab as therapeutic option is reinforced by our recent observation that ALCAM, the CD6 ligand, is overexpressed and that CD6-positive T and B cells are detected within salivary glands from Sjögren's syndrome patients. In this study, itolizumab-positive target cells were characterized within both peripheral blood and salivary glands in order to provide rational for anti-CD6 treatment in Sjögren's syndrome.
- Published
- 2013
- Full Text
- View/download PDF